Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Botulinum toxin type a
Drug ID BADD_D00290
Description In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.[A231824] With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions.[A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.[L32494,L32559]
Indications and Usage For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.
Marketing Status Not Available
ATC Code M03AX01
DrugBank ID DB00083
KEGG ID D00783
MeSH ID D019274
PubChem ID Not Available
TTD Drug ID D0D1RM
NDC Product Code 15054-0500; 0299-5962; 0023-1111; 15054-0530
Synonyms Botulinum Toxins, Type A | Clostridium botulinum A Toxin | Botulinum Toxin A | Toxin A, Botulinum | Botulinum Neurotoxin A | Neurotoxin A, Botulinum | Botulinum A Toxin | Toxin, Botulinum A | Botulinum Toxin Type A | Botulinum Neurotoxin Type A | Clostridium Botulinum Toxin Type A | Meditoxin | Botox | Neuronox | Oculinum | Vistabex | OnabotulinumtoxinA | Onabotulinumtoxin A | Vistabel
Chemical Information
Molecular Formula Not Available
CAS Registry Number 93384-43-1
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blepharospasm17.17.02.001; 06.05.01.001--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dysarthria19.19.03.001; 17.02.08.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye swelling06.08.03.003--Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Eyelid ptosis17.17.02.004; 06.05.01.002--Not Available
Facial pain08.01.08.012--
Gastrointestinal disorder07.11.01.001--Not Available
Headache17.14.01.001--
Herpes zoster23.09.03.002; 11.05.02.003--
Hypersensitivity10.01.03.003--
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Injection site haematoma24.07.01.009; 08.02.03.004; 12.07.03.004--Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
The 1th Page    1 2    Next   Last    Total 2 Pages